Jump to main content
Jump to site search
Access to RSC content Close the message box

Continue to access RSC content when you are not at your institution. Follow our step-by-step guide.


Issue 8, 2013
Previous Article Next Article

An HPLC-DAD method for the simultaneous quantification of opicapone (BIA 9-1067) and its active metabolite in human plasma

Author affiliations

Abstract

Opicapone (BIA 9-1067) is a novel catechol-O-methyltransferase inhibitor presently under clinical development as an adjuvant in the pharmacotherapy of Parkinson's disease. This report describes the development and validation of a bioanalytical assay for the simultaneous quantification of opicapone and its active metabolite (BIA 9-1079) in human plasma. The method herein reported is based on high-performance liquid chromatography coupled with diode-array detection (HPLC-DAD) and the sample preparation consists of a plasma protein precipitation step followed by liquid–liquid extraction. Chromatographic separation of the analytes (opicapone and BIA 9-1079) and the internal standard (tamoxifen) was achieved in less than 10 min on a reversed-phase C18 column at 25 °C by applying a gradient elution program using a mobile phase composed of 0.05 M monosodium phosphate solution adjusted to pH 2.45 (A) and acetonitrile (B) pumped at 0.8 mL min−1. Opicapone and the internal standard were monitored at 271 nm while BIA 9-1079 was assessed at 257 nm. Calibration curves of both analytes were linear (r2 ≥ 0.997) in the concentration range of 25–3000 ng mL−1 and their limits of quantification were established to be 25 ng mL−1. The overall precision did not exceed 13.2% and the accuracy was within ±11.1%. Several drugs potentially co-administered with opicapone were tested and they did not interfere at the retention times of the analytes (opicapone and BIA 9-1079) and internal standard. The method was then successfully applied for quantifying opicapone and its active metabolite (BIA 9-1079) in plasma samples obtained from a healthy subject enrolled in a clinical trial.

Graphical abstract: An HPLC-DAD method for the simultaneous quantification of opicapone (BIA 9-1067) and its active metabolite in human plasma

Back to tab navigation

Article information


Submitted
12 Nov 2012
Accepted
14 Feb 2013
First published
15 Feb 2013

Analyst, 2013,138, 2463-2469
Article type
Paper

An HPLC-DAD method for the simultaneous quantification of opicapone (BIA 9-1067) and its active metabolite in human plasma

D. Gonçalves, G. Alves, A. Fortuna, P. Soares-da-Silva and A. Falcão, Analyst, 2013, 138, 2463
DOI: 10.1039/C3AN36671E

Social activity

Search articles by author

Spotlight

Advertisements